ACME UNITED CORP (ACU) stock intrinsic value fair value estimate & owner earnings analysis

Acme United is a 150-year-old maker and marketer of first-aid and safety kits (First Aid Only, PhysiciansCare, Spill Magic absorbents), trauma and emergency products (MyMedic, bought January 2026) and cutting and sharpening tools (Westcott scissors, Clauss, DMT). It sells mostly through large retailers, office-supply and school distributors and its own websites. Two customers were each about 13% of 2025 sales, and some school and office goods are sourced from China, so tariffs and a few buyers matter a great deal. HOW WE MEASURE THE CASH IT EARNS. We start with cash from operations, strip out swings in receivables, inventory and payables, subtract stock compensation as a real cost, and subtract only the spending needed to keep the business where it is. Per share that came to $1.94, $1.24, $1.61, $2.28, $3.22, $2.26, $0.99, $2.55, $2.44 and $2.08 for 2016 through 2025. We then add back interest actually paid, so the business is valued before its lenders and the debt is deducted separately: roughly $9.8M in 2021, $5.8M in 2022, $12.5M in 2023, $11.9M in 2024 and $10.1M in 2025. ONE JUDGEMENT CHANGES THE 2025 FIGURE. Spending in 2025 included about $6.0M to buy a 77,000 square foot plant in Mt. Pleasant, Tennessee on July 15, 2025. The annual report describes it as capacity expansion for the growing Spill Magic business, not a replacement, so we treat it as investment for growth rather than a cost of standing still. Without it, 2025 spending was about $4.7M, close to depreciation, and 2025 cash before lenders was about $16.0M. We do not take that $16.0M as the level. We use the median of 2021 to 2025, about $11.9M. That window covers the post-pandemic inventory squeeze, the November 2023 sale of a product line worth about 6% of sales, and the recent tariff disruption. We exclude the 2021 loan forgiveness and the 2023 gain on the business sale, neither of which was operating cash. GROWTH CHECK. On a strict basis that charges the whole plant, cash before lenders fell 15% in 2025. Treating the plant as growth spending, it rose. Our base case assumes no growth in the first year or after it, so it does not depend on which reading is right. WHAT WE CREDIT AND WHAT WE LEAVE OUT. Credited: MyMedic, bought and paid for at $18.7M ($14.6M at closing, $4.1M still owed). Second-quarter 2026 sales rose 16% to $62.7M and operating income rose 7%, but first-half operating income was 3% lower than a year earlier because of integration costs. With only two quarters of evidence we credit about $1.0M a year. We also credit the staying power of the brands, since cash generation has stayed in a band for ten years through the pandemic and an inventory squeeze, and workplace first-aid kits must be restocked to meet safety rules. Not credited: new products, market-share gains, output from the new Tennessee capacity, future acquisitions, margin gains or tariff relief. Intangible amortization of about $2.5M a year is added back as a non-cash charge. We found no sign that the acquired brands are fading, so we hold the level flat rather than letting it grow. BASE CASE ($43.35 per share). About $12.9M a year, flat and continuing indefinitely, on the record of brands that have lasted decades. The business is worth about $215M ($51.92 a share). It owes about $35.5M ($8.57 a share). That leaves about $180M, or $43.35. BEAR CASE ($15.77). Two downturn years at about $6.0M. That repeats the 2022 squeeze, when inflation and inventory problems cut cash before lenders to $5.8M, and adds the late-2025 cancellations of school and office orders after tariffs. After that, the case assumes one of the two 13% customers is lost and MyMedic adds little, holding cash at about $8.0M through year ten, then eroding 3% a year. The revolver is refinanced at about 1.5 points more, adding about $2.5M to the debt burden. Interest is still covered more than two times at the trough. The business is worth about $103M ($24.95 a share). It owes about $38.0M ($9.18 a share). That leaves about $65M, or $15.77. BULL CASE ($56.85). MyMedic reaches its recent pace, adding about $2.0M a year in total. The business keeps adding small brands and capacity as it has, which lifts cash 2% a year for ten years, below the roughly 3% dollar growth of the last decade. After that it holds flat. The business is worth about $271M ($65.42 a share). It owes about $35.5M. That leaves about $235M, or $56.85. DEBT. At June 30, 2026 the company had $22.6M drawn on its $65M HSBC revolver (up from $11.9M at year-end, mainly to pay for MyMedic). The revolver costs SOFR plus 1.70% and matures May 31, 2027. There is also about $9.7M of 3.8% fixed-rate mortgage debt on the Rocky Mount, North Carolina and Vancouver, Washington facilities, due December 1, 2031, and $4.1M still owed to MyMedic's sellers. We treat the $5.0M of cash as needed to run the business. Because the mortgage is cheap, it is worth about $0.9M less than its face value as a burden on shareholders. The revolver maturity is the date that matters. The facility has been extended eleven times and the company has stayed in compliance. WHAT COULD MAKE US WRONG. We tested whether the recent jump in sales has reached profits. First-half 2026 sales rose 15%, but operating income did not rise with them, which is why we credit MyMedic cautiously. If the 2025 spending on the Tennessee plant is really ongoing spending rather than a one-time expansion, the normal level is closer to $10.1M and the shares are worth roughly $32 on the base path. The mortgage balance at June 30, 2026 is estimated from the year-end figure of $9.98M because the quarterly report did not break it out. MARGIN OF SAFETY PRICE ($21, once the revolver is renewed). How sure are we of the level? Fairly sure of the range and less sure of the exact figure. Ten years of results sit between about $5.8M and $12.5M of cash before lenders, and the main open question is how much of the 2025 spending will recur. The worst plausible outcome is losing a 13% customer during a retail or tariff downturn just as the revolver has to be renewed. With debt of about $36M against a business earning $6M to $12M, that is survivable, but shareholders would wait years. If we are wrong about the plant spending and about MyMedic, the shares are worth about $32. If the bear case plays out, they are worth about $16. At $21, the business earns about $2.70 a share in a normal year and pays about $0.60 a share in dividends while waiting. Reaching a value in the low $30s within two to three years, even on the cautious reading, would imply the target return. Below $21 the bear case is the only path that implies a loss, and that path needs both a customer loss and a downturn. The margin-of-safety price applies only after the May 2027 revolver is renewed on similar terms, because a small company that cannot roll its main credit line has none of these choices.